Cogent Biosciences, Inc. Common Stock (COGT) Stock
NASDAQ · COGT
31.41
Fundamentals
Market cap
$5.61B
Price / Earnings ratio
-14.5x
Price / Sales ratio
N/A
Price / Book ratio
10.2x
Return on assets
-56.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
NeutralCOGTAugust 13, 2026
Zacks Investment ResearchNeutral
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
COGT

Proactive Investors
Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts
NeutralCOGTMarch 30, 2026
Proactive InvestorsNeutral
Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts
COGT

The Motley Fool
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
NeutralCOGTMarch 21, 2026
The Motley FoolNeutral
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
COGT

The Motley Fool
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
NeutralCOGTMarch 21, 2026
The Motley FoolNeutral
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
COGT
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy4
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
1B743M371M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-328.9M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
NeutralCOGTAugust 13, 2026
Zacks Investment ResearchNeutral
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
COGT

Proactive Investors
Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts
NeutralCOGTMarch 30, 2026
Proactive InvestorsNeutral
Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts
COGT

The Motley Fool
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
NeutralCOGTMarch 21, 2026
The Motley FoolNeutral
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
COGT

The Motley Fool
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
NeutralCOGTMarch 21, 2026
The Motley FoolNeutral
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
COGT

The Motley Fool
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026
NeutralCOGTMarch 20, 2026
The Motley FoolNeutral
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026
COGT

Zacks Investment Research
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM
NeutralCOGTMarch 17, 2026
Zacks Investment ResearchNeutral
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM
COGT

The Motley Fool
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned
NeutralCOGTMarch 13, 2026
The Motley FoolNeutral
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned
COGT

The Motley Fool
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million
NeutralCOGTFebruary 17, 2026
The Motley FoolNeutral
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million
COGT

The Motley Fool
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough
NeutralCOGTFebruary 17, 2026
The Motley FoolNeutral
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough
COGT

The Motley Fool
Large Biotech Fund Sells Shares of Cogent Biosciences for Over $120M
NeutralCOGTFebruary 1, 2026
The Motley FoolNeutral
Large Biotech Fund Sells Shares of Cogent Biosciences for Over $120M
COGT
About Cogent Biosciences, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees258
CEOMr. Andrew R. Robbins M.B.A.
IPO DateMar 29, 2018
HeadquartersWaltham, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Andrew R. Robbins M.B.A. | President, CEO & Director | 1976 |
| Mr. John L. Green C.A., CPA | CFO & Principal Accounting Officer | 1980 |
| Dr. John Edward Robinson Ph.D. | Chief Scientific Officer | 1974 |
| Dr. Jessica Sachs M.D. | Chief Medical Officer | 1975 |
| Mr. Cole Pinnow | Chief Commercial Officer | 1975 |
| Mr. Brad Barnett | Chief Technology Officer | — |
| Ms. Christi Waarich | Senior Director of Investor Relations | — |
| Mr. Evan D. Kearns J.D. | Chief Legal Officer & Corporate Secretary | 1980 |
| Mr. Abb Hayden | Senior Vice President of Sales | — |
| Ms. Erin Schellhammer | Chief People Officer | — |
Fundamentals
Valuation
Market cap$5.61B
Price-to-sales ratioN/A
Price-to-book value10.24
Price-earnings ratio-14.50
Return on Equity-83.00%
Return on SalesN/A
Return on Assets-56.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-2.16
Income Statement
Average volume1,885,487
EBITDA$-345.43M
1 year high (52w)$43.73
1 year low (52w)$12.97
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
4 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$54.25
Est return
67.70%